Portfolio
ONL Therapeutics
FAS apoptosis inhibitors to protect photoreceptors and preserve patient vision from retinal diseases. ONL is focused on preventing the death of key retinal cells, including photoreceptors—the root cause of vision loss and the leading cause of blindness.(2014)
PhasiQ
Solution microarrays for sensitive quantitation of any combination of protein biomarkers without false signals(2014)
Arborlight, LLC
Dynamic daylight emulation system with environmental feedback controls(2013)
Millendo
Development of novel therapy for the treatment of adrenal cancer (Formerly Atterocor)(2013)
OncoFusion Therapeutics, Inc.
Personalized therapeutics for patients with genetically defined cancers(2013)
AlertWatch
Produces patient monitoring and clinical decision support systems OR and ICU.(2012)
ChemXlerate
Tools to identify crystalline forms of active pharmaceutical ingredients(2012)
Prytime Medical
A medical device company that designs, develops and markets minimally invasive solutions for vascular trauma.(2012)